SG11201505210RA - Characterizing a glatiramer acetate related drug product - Google Patents
Characterizing a glatiramer acetate related drug productInfo
- Publication number
- SG11201505210RA SG11201505210RA SG11201505210RA SG11201505210RA SG11201505210RA SG 11201505210R A SG11201505210R A SG 11201505210RA SG 11201505210R A SG11201505210R A SG 11201505210RA SG 11201505210R A SG11201505210R A SG 11201505210RA SG 11201505210R A SG11201505210R A SG 11201505210RA
- Authority
- SG
- Singapore
- Prior art keywords
- characterizing
- drug product
- glatiramer acetate
- related drug
- acetate related
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title 1
- 229940126534 drug product Drugs 0.000 title 1
- 229960003776 glatiramer acetate Drugs 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749228P | 2013-01-04 | 2013-01-04 | |
| US201361819481P | 2013-05-03 | 2013-05-03 | |
| PCT/US2014/010103 WO2014107533A2 (en) | 2013-01-04 | 2014-01-02 | Characterizing a glatiramer acetate related drug product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201505210RA true SG11201505210RA (en) | 2015-07-30 |
Family
ID=51061235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201505210RA SG11201505210RA (en) | 2013-01-04 | 2014-01-02 | Characterizing a glatiramer acetate related drug product |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20140193827A1 (enExample) |
| EP (1) | EP2941274A4 (enExample) |
| JP (1) | JP2016504039A (enExample) |
| KR (1) | KR20150111945A (enExample) |
| CN (1) | CN105228651A (enExample) |
| AU (1) | AU2014204043A1 (enExample) |
| BR (1) | BR112015016169A2 (enExample) |
| CA (1) | CA2896957A1 (enExample) |
| CL (1) | CL2015001915A1 (enExample) |
| EA (1) | EA201591251A1 (enExample) |
| HK (1) | HK1216299A1 (enExample) |
| IL (2) | IL239692A0 (enExample) |
| MX (1) | MX2015008754A (enExample) |
| PE (1) | PE20151980A1 (enExample) |
| SG (1) | SG11201505210RA (enExample) |
| WO (1) | WO2014107533A2 (enExample) |
| ZA (1) | ZA201505367B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ598661A (en) | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| HK1213830A1 (zh) | 2012-10-10 | 2016-07-15 | Teva Pharmaceutical Industries Ltd. | 用於预测醋酸格拉替雷临床反应的生物标志物 |
| CN105377308B (zh) | 2013-03-14 | 2019-07-26 | 迈兰公司 | 醋酸格拉替雷响应生物标志物mRNA效力测定 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9995734B2 (en) | 2013-10-24 | 2018-06-12 | Mylan Inc. | Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| JP2018506275A (ja) | 2015-01-28 | 2018-03-08 | ジェネンテック， インコーポレイテッド | 多発性硬化症の遺伝子発現マーカー及び治療 |
| WO2017087866A1 (en) | 2015-11-20 | 2017-05-26 | Grand Valley State University | Nato3 mutant polypeptides and uses thereof |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| JP7276664B2 (ja) * | 2016-11-11 | 2023-05-18 | ロングエバーオン インコーポレイテッド | 細胞性及び体液性免疫を達成するためのヒト間葉系幹細胞を使用する方法 |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| CN115044684A (zh) * | 2022-06-22 | 2022-09-13 | 四川大学华西医院 | lcn2基因作为生物标记物在检测Stat5基因是否缺失中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7429374B2 (en) * | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
| WO2004028339A2 (en) * | 2002-09-27 | 2004-04-08 | Brigham And Women's Hospital, Inc. | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
| JP2009509142A (ja) * | 2005-09-19 | 2009-03-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 調節性Ｔ細胞機能をモジュレート（ｍｏｄｕｌａｔｅ）し得るＧＰＲ８３アゴニストおよびＧＰＲ８３アンタゴニストを同定するための方法 |
| US8753833B2 (en) * | 2007-06-21 | 2014-06-17 | Momenta Pharmaceuticals, Inc. | Copolymer assay |
| EP2365825A1 (en) * | 2008-11-18 | 2011-09-21 | Crossbeta Biosciences B.V. | Cross-beta structures as carriers in vaccines |
| NZ598661A (en) * | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
-
2014
- 2014-01-02 MX MX2015008754A patent/MX2015008754A/es unknown
- 2014-01-02 EA EA201591251A patent/EA201591251A1/ru unknown
- 2014-01-02 HK HK16104285.8A patent/HK1216299A1/zh unknown
- 2014-01-02 SG SG11201505210RA patent/SG11201505210RA/en unknown
- 2014-01-02 JP JP2015551759A patent/JP2016504039A/ja active Pending
- 2014-01-02 EP EP14735255.3A patent/EP2941274A4/en not_active Withdrawn
- 2014-01-02 CA CA2896957A patent/CA2896957A1/en not_active Abandoned
- 2014-01-02 WO PCT/US2014/010103 patent/WO2014107533A2/en not_active Ceased
- 2014-01-02 BR BR112015016169A patent/BR112015016169A2/pt not_active IP Right Cessation
- 2014-01-02 KR KR1020157021141A patent/KR20150111945A/ko not_active Withdrawn
- 2014-01-02 CN CN201480008231.5A patent/CN105228651A/zh active Pending
- 2014-01-02 AU AU2014204043A patent/AU2014204043A1/en not_active Abandoned
- 2014-01-02 PE PE2015001246A patent/PE20151980A1/es not_active Application Discontinuation
- 2014-01-03 US US14/147,167 patent/US20140193827A1/en not_active Abandoned
-
2015
- 2015-06-29 IL IL239692A patent/IL239692A0/en unknown
- 2015-07-03 CL CL2015001915A patent/CL2015001915A1/es unknown
- 2015-07-24 ZA ZA2015/05367A patent/ZA201505367B/en unknown
-
2017
- 2017-05-28 IL IL252547A patent/IL252547A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2015001915A1 (es) | 2016-11-11 |
| BR112015016169A2 (pt) | 2017-07-11 |
| EA201591251A1 (ru) | 2016-05-31 |
| KR20150111945A (ko) | 2015-10-06 |
| IL252547A0 (en) | 2017-07-31 |
| IL239692A0 (en) | 2015-08-31 |
| EP2941274A4 (en) | 2016-11-16 |
| PE20151980A1 (es) | 2016-01-15 |
| ZA201505367B (en) | 2016-11-30 |
| MX2015008754A (es) | 2016-04-11 |
| WO2014107533A2 (en) | 2014-07-10 |
| EP2941274A2 (en) | 2015-11-11 |
| CN105228651A (zh) | 2016-01-06 |
| US20140193827A1 (en) | 2014-07-10 |
| HK1216299A1 (zh) | 2016-11-04 |
| WO2014107533A3 (en) | 2015-01-29 |
| AU2014204043A1 (en) | 2015-08-13 |
| CA2896957A1 (en) | 2014-07-10 |
| JP2016504039A (ja) | 2016-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201505367B (en) | Characterizing a glatiramer acetate related drug product | |
| IL245544A0 (en) | drug delivery system | |
| IL240846A0 (en) | drug combination | |
| EP3010681A4 (en) | Providing a pharmacokinetic drug dosing regime | |
| SG11201507595XA (en) | Processes and intermediates for preparing a medicament | |
| EP2953670A4 (en) | DONOR FOR MEDICINAL PRODUCTS | |
| ZA201507576B (en) | Pharmaceutical combination drug | |
| PT3024755T (pt) | Cápsula para produtos de infusão | |
| AU353238S (en) | A chocolate tablet | |
| GB201318686D0 (en) | Pharmaceutical preparations | |
| IL245705B (en) | Pharmaceutical dosage forms | |
| ZA201600027B (en) | Pharmaceutical preparation | |
| GB201301721D0 (en) | Pharmaceutical Preparations | |
| GB201313835D0 (en) | A medicament | |
| PT3044124T (pt) | Cápsula para produtos de infusão | |
| GB201315026D0 (en) | A novel pharmaceutical product combination | |
| GB201319467D0 (en) | A pharmaceutical component-mixing delivery assembly | |
| ZA201506465B (en) | Pharmaceutical preparation | |
| IL240533A0 (en) | Processes and intermediates for drug preparation | |
| GB201320786D0 (en) | Medicament | |
| GB201316662D0 (en) | Pharmaceutical Combination | |
| GB201309971D0 (en) | Oral medicines syringe |